Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage
Executive Summary
Seventeen of the panelists voted that the clinical data support approval for some of Braeburns proposed doses, but no one supported the highest proposed monthly dose.
You may also be interested in...
While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Shutdown Edition
The latest drug development news and highlights from our US FDA Performance Tracker.